Latest News and Press Releases

Amsterdam, the Netherlands, and Holzgerlingen, Germany, October 30, 2019, 10:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level...

Blinded evaluation study with leading global IVD player demonstrated diagnostic performance in line with FDA requirements for antibiotic susceptibility testing (AST)Already received orders for...

- Strategic transaction to combine businesses with OpGen Inc. - Revenues increased by approximately 35% year-on-year - Progressing regulatory product approvals in the U.S. and China Amsterdam,...

R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbPartner to fund R&D and obtains option to license ARESdb and ARES Technology Platform for...

Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for...

Investment bank supports Curetis in assessment of all strategic and tactical financing options   Publication of H1-2019 financials postponed to September 18, 2019Key financials show EUR 7.8...

Initial focus on non-diagnostic testing with Next Generation Sequencing (NGS) for infection control, outbreak management and researchFirst commercial orders received and processed Vienna,...

- Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible bonds has been reached - Curetis elects to settle the excess entitlement under the first...

- AKO MED to exclusively distribute Unyvero A50 portfolio in Serbia, North Macedonia, Bosnia Hercegovina, and Montenegro   - Preparing inclusion of Unyvero in several regional tender offers ...

Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the "Company" and, together with Curetis USA Inc. and Curetis GmbH,...